NEWSLETTERS - The Huntington's Disease News
By AICH - Roma Onlus
View this email in your browser
Newsletters 20 Ott.  2016
Huntington's disease news
Ott. 20,  2016
Ionis Phase I Huntington’s disease trial at halfway mark: ‘No surprises so far’ means good news

At its halfway mark, Ionis Pharmaceuticals’ historic Huntington’s disease Phase 1 gene-silencing clinical trial is on track to finish as scheduled in late 2017, company officials said in an interview on September 26.


Ott. 12  2016
Research Will Explore New Therapies for Huntington’s Disease

A new award from the CHDI Foundation will advance promising research that aims to slow the progression of Huntington’s disease.  The funding, anticipated to total more than $10.5 million over next five years, will help University of Rochester Medical Center (URMC) scientists develop a stem cell-based therapy that swaps sick brain cells for healthy ones


Sett 20, 2016
An open approach to Huntington’s disease research

Guest post by Rachel Harding, postdoctoral fellow at the Structural Genomics Consortium, University of Toronto, Canada

Huntington’s disease (HD) is a fatal neurodegenerative disorder caused by a mutation in the huntingtin gene1.


Ott. 19, 2016
Huntington’s disease modifier genes – the role of Mlh1

Huntington’s disease (HD) is a dominantly inherited disorder. HD is a neurodegenerative disease, with cognitive decline, behavioral symptoms and chorea. The
Huntingtin gene (HTT) normally contains 6-35 CAG repeats encoding a glutamine tract in the huntingtin protein.

Ott. 13, 2016
Application for Treatments of Parkinson’s Disease, Alzheimer’s Disease, Huntington’s Disease and Dementia

Growblox Sciences, Inc. (OTCQB: GBLX) is pleased to announce the filing of the first of several patent applications for life science inventions by its wholly-owned subsidiary, Growblox Life Sciences, LLC.  The current provisional patent application covers complex-cannabinoid-containing mixtures capable of enhancing dopamine secretion and protect neurons from the mitochondrial-induced free radical damage that occurs during disease progression in the brains of patients with Parkinson’s disease, Alzheimer’s disease, Lewy Body Dementia, and Huntington’s disease, among others. 

Copyright © 2016 aichroma, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

Email Marketing Powered by Mailchimp